1.
Cancer Immunol Res
; 12(8): 952-953, 2024 Aug 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38967231
RESUMEN
Sex differences in cancer survivorship and response to immunotherapy have been observed, with males generally displaying better outcomes to immune checkpoint blockade compared with females. In this article, by interrogating public lung cancer sequencing datasets, Brennan and colleagues uncover a chemokine axis that may contribute to disparate immunotherapy outcomes between the sexes. See related article by Brennan et al., p. 956 (3).